Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 224 for your search:
Cancer Type/Condition:
Breast cancer, female
Stage/Subtype:
stage IIIA breast cancer
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Aromatase Inhibitor Clinical Trial
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
40 to 70
Sponsor:
NIGMS
Protocol IDs:
0412-14
, UO1-GM61373-06, NCT00228956
2.
Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 45
Sponsor:
Other
Protocol IDs:
0501-37
, NCT00352872
3.
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Phase:
Phase IV
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
26658
, NCT00872859
4.
Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to "Low-Risk" Breast Cancer Patients
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
50 and over
Sponsor:
Other
Protocol IDs:
S07-002
, 1098558, NCT00882596
5.
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GCO# 08-1373
, NCT00900744
6.
Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection
Phase:
Phase IV
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
08-09-14B
, NCT00984269
7.
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
Other
Protocol IDs:
20050113
, NCT00243685
8.
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
Postmenopausal
Sponsor:
NCI
Protocol IDs:
ACOSOG-Z1031
, CALGB-ACOSOG-Z1031, SDC1, NCT00265759
9.
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
WHC-MRI-GU-2006-097
, NCT00397761
10.
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
65 and over
Sponsor:
Other
Protocol IDs:
0120070323
, NCT00698971
11.
Letrozole After Tamoxifen in Treating Women With Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Postmenopausal
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CAN-NCIC-MA17
, CALGB-49805, E-JMA17, EORTC-10983, IBCSG-BIG97-01, NCCTG-JMA17, SWOG-JMA17, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17, NCT00003140, JMA17, MA17
12.
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Premenopausal
Sponsor:
NCI
Protocol IDs:
IBCSG-2402
, BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13
13.
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Premenopausal
Sponsor:
NCI
Protocol IDs:
IBCSG-25-02
, BIG-3-02, NABCI-IBCSG-25-02, EU-20347, NCT00066703, EUDRACT-2004-000168-28
14.
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0221
, S0221, NCT00070564
15.
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
ID99-146
, NCT00038402
16.
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NSABP-B-40
, NCT00408408
17.
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Other
Protocol IDs:
CDR0000528955
, U10CA021115, ECOG-E5103, NCT00433511
18.
Regional Anesthesia and Breast Cancer Recurrence
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 85
Sponsor:
Other
Protocol IDs:
06-692
, NCT00418457
19.
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
NSABP B-41
, NCT00486668
20.
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EGF106708
, BIG 2-06/N063D/MAC13, NCT00490139
21.
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ACOSOG-Z1041
, Z1041, NCT00513292
22.
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CLEOPATRA)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
TOC4129g
, WO20698, NCT00567190
23.
Combination Chemotherapy Followed By Docetaxel or Ixabepilone in Treating Patients Who Have Undergone Surgery for Nonmetastatic Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
FNCLCC-PACS-08/0610
, FNCLCC-PACS 08/0610 – TavIx, EU-20804, FNCLCC-Tavlx, BMS-FNCLCC-PACS-08/0610, AMGEN-FNCLCC-PACS-08/0610, NCT00630032
24.
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
NSABP B-44-I
, CIRG (TRIO) 011, Roche BO20906, BETH, NCT00625898
25.
Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CZOL446H US113
, NCT00712985
Select All on Page
1
Help with Results
